Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing

Area of Science:

• Virology
• Infectious Diseases
• Pharmacology

Background:

• Ebola virus disease (EVD) presents a significant public health challenge with high fatality rates and limited treatment options.
• Statins, commonly used for cholesterol management, possess diverse biological activities and were previously considered for adjunct EVD therapy.

Purpose of the Study:

• To investigate the in vitro antiviral efficacy of statins against Ebola virus (EBOV) infection.
• To elucidate the molecular mechanisms underlying statin's effect on EBOV replication and infectivity.

Main Methods:

• Evaluated statin (lovastatin) treatment on EBOV-infected primary human macrophages and Huh7 cells.
• Assessed viral entry, infectious virus production, and viral glycoprotein processing.
• Investigated the role of mevalonate and low-density lipoprotein in statin's antiviral effects.

Main Results:

• Statin treatment significantly reduced infectious EBOV production in both cell types.
• Statin's effect was linked to inhibited viral glycoprotein processing, not viral entry.
• Exogenous mevalonate, but not LDL, reversed statin-induced inhibition, indicating a role for cholesterol biosynthesis.
• Statin-treated cells produced EBOV particles lacking surface glycoproteins, rendering them non-infectious.

Conclusions:

• Statin treatment effectively inhibits EBOV infection by disrupting viral glycoprotein processing and virion infectivity.
• Statins represent a promising, cost-effective therapeutic avenue for EVD, warranting further investigation in animal models.
• The anti-inflammatory and immunomodulatory properties of statins may further contribute to their potential in managing EVD.